Dosage regimen for a pi-3 kinase inhibitor

Abstract

The present invention relates to a dosage regimen for a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a dosage regimen for the treatment of patients suffering from a proliferative disease, such as, for example, cancer, with a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof.

1 - 15 . (canceled) 
     
     
         16 . A method of treating cancer selected from head and neck cancer in a human patient in need of such treatment, comprising administering to said human patient a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof in a therapeutically effective amount of 60 to 120 mg daily. 
     
     
         17 . The method according to  claim 16 , wherein the compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof is administered in a therapeutically effective amount of 100 mg daily. 
     
     
         18 . The method according to  claim 16 , wherein the compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof is administered in combination with at least one additional therapeutic agent.